Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis

Kanto Study, Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20%, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47%, 24%, 8%, and 0% for Good (Score 0, 1: n = 118), Intermediate-1 (Score 2: n = 75), Intermediate-2 (Score 3: n = 39), and Poor (Score 4: n = 24), respectively (P < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Unrelated Donors
Survival
Validation Studies
Karyotype
C-Reactive Protein
Population
Multicenter Studies
Stem Cells
Multivariate Analysis
Retrospective Studies
Bone Marrow
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation : a KSGCT multicenter analysis. / Kanto Study; Group for Cell Therapy (KSGCT).

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

@article{d9604ac8abd64b3bbc46fffb591fb9b1,
title = "Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis",
abstract = "A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20{\%}, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47{\%}, 24{\%}, 8{\%}, and 0{\%} for Good (Score 0, 1: n = 118), Intermediate-1 (Score 2: n = 75), Intermediate-2 (Score 3: n = 39), and Poor (Score 4: n = 24), respectively (P < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.",
author = "{Kanto Study} and {Group for Cell Therapy (KSGCT)} and Takayoshi Tachibana and Junya Kanda and Takuma Ishizaki and Yuho Najima and Masatsugu Tanaka and Noriko Doki and Fujiwara, {Shin ichiro} and Kimura, {Shun ichi} and Makoto Onizuka and Satoshi Takahashi and Takeshi Saito and Takehiko Mori and Shin Fujisawa and Emiko Sakaida and Kenji Matsumoto and Nobuyuki Aotsuka and Moritaka Goto and Reiko Watanabe and Katsuhiro Shono and Kensuke Usuki and Nobuhiro Tsukada and Heiwa Kanamori and Yoshinobu Kanda and Shinichiro Okamoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0494-9",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation

T2 - a KSGCT multicenter analysis

AU - Kanto Study

AU - Group for Cell Therapy (KSGCT)

AU - Tachibana, Takayoshi

AU - Kanda, Junya

AU - Ishizaki, Takuma

AU - Najima, Yuho

AU - Tanaka, Masatsugu

AU - Doki, Noriko

AU - Fujiwara, Shin ichiro

AU - Kimura, Shun ichi

AU - Onizuka, Makoto

AU - Takahashi, Satoshi

AU - Saito, Takeshi

AU - Mori, Takehiko

AU - Fujisawa, Shin

AU - Sakaida, Emiko

AU - Matsumoto, Kenji

AU - Aotsuka, Nobuyuki

AU - Goto, Moritaka

AU - Watanabe, Reiko

AU - Shono, Katsuhiro

AU - Usuki, Kensuke

AU - Tsukada, Nobuhiro

AU - Kanamori, Heiwa

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20%, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47%, 24%, 8%, and 0% for Good (Score 0, 1: n = 118), Intermediate-1 (Score 2: n = 75), Intermediate-2 (Score 3: n = 39), and Poor (Score 4: n = 24), respectively (P < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.

AB - A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20%, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47%, 24%, 8%, and 0% for Good (Score 0, 1: n = 118), Intermediate-1 (Score 2: n = 75), Intermediate-2 (Score 3: n = 39), and Poor (Score 4: n = 24), respectively (P < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.

UR - http://www.scopus.com/inward/record.url?scp=85066797627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066797627&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0494-9

DO - 10.1038/s41375-019-0494-9

M3 - Article

C2 - 31147621

AN - SCOPUS:85066797627

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -